Traduction de «Maladie à » (Français → Anglais) :

trinucleotide repeat disorder | triplet repeat disorder | trinucleotide repeat disease | triplet repeat expansion disorder | trinucleotide-repeat expansion disease | disorder caused by expansion of triplet repeats

prion disease

notifiable disease [ reportable disease | named disease ]

CAG repeat neurological disorder | CAG repeat disorder

Convention respecting transfers of insured persons from one sick fund to another and respecting sickness benefit during temporary residence

immune-complex disease | immune-complex disorder

Swiss League for Patients with Tick-borne Diseases

infectious disease [ bacterial disease | cholera | communicable disease | contagious disease | leprosy | malaria | parasitic disease | sleeping sickness | trypanosomiasis | tuberculosis | viral disease | viral diseases | yellow fever ]

sick building syndrome (1) | tight building syndrome(2) [ SBS ]

mentally ill offender | mentally disordered offender

Specific activities shall include: understanding the determinants of health (including nutrition, physical activity and gender, and environmental, socio-economic, occupational and climate-related factors); improving health promotion and disease prevention; understanding disease and improving diagnosis and prognosis; developing effective prevention and screening programmes and improving the assessment of disease susceptibility; improving the surveillance of infectious diseases and preparedness for combating epidemics and emerging diseases; developing new and better preventive and therapeutic vaccines and drugs; using in-silico medicine for improving disease management and prediction; developing regenerative medicine and adapted treatm ...[+++]ents, and treating disease, including palliative medicine; transferring knowledge to clinical practice and scalable innovation actions; improving health information and better collection and use of health cohort and administrative data; standardised data analysis and techniques; active ageing, and independent and assisted living; individual awareness and empowerment for self-management of health; promotion of integrated care, including psychosocial aspects; improving scientific tools and methods to support policy making and regulatory needs; optimising the efficiency and effectiveness of healthcare provision; and reducing health disparities and inequalities by evidence-based decision making and dissemination of best practice and by innovative technologies and approaches.

Council Directive 2002/60/EC of 27 June 2002 laying down specific provisions for the control of African swine fever and amending Directive 92/119/EEC as regards Teschen disease and African swine fever (4) deleted Teschen disease (porcine enterovirus encephalomyelitis) from the list of diseases laid down in Annex I to Council Directive 92/119/EEC of 17 December 1992 introducing general Community measures for the control of certain animal diseases and specific measures relating to swine vesicular disease (5) and consequently by Commission Decision 2008/650/EC of 30 July 2008 amending Council Directive 82/894/EEC on the notification of anim ...[+++]al diseases within the Community to include certain diseases in the list of notifiable diseases and to delete porcine enterovirus encephalomyelitis from that list (6) that disease was deleted from the list of the compulsorily notifiable diseases within the Union.

Maintain the EU’s coordinative role in the development of the EU policy on rare diseases and to support Member States in their activities on the national level. Continue to support the development of high quality National Rare Diseases Plans/Strategies in the European Union. Provide continued support for the International Rare Disease Research Consortium and initiatives developed under its umbrella. Continue to ensure proper codification of rare diseases. Work further to decrease inequalities between patients with rare diseases and patients suffering from more common disorders and to support initiatives promoting equal access to diagnosi ...[+++]s and treatment. Continue to promote patients empowerment in all aspects of rare diseases policy development Continue activities increasing public awareness about rare diseases and EU activity in this field Make use of the Directive 2011/24/EU on the application of patients’ rights in cross-border healthcare to bring together European Reference Networks on rare diseases. Support the development of the tools facilitating cooperation and interoperability of the European Reference Networks for rare diseases. Stimulate development and use of eHealth solutions in the area of rare diseases. Implement and continue support for the European Platform on rare diseases registration. Continue playing a global role in the rare diseases initiative and collaborating with important international stakeholders.

Maintain the EU’s coordinative role in the development of the EU policy on rare diseases and to support Member States in their activities on the national level. Continue to support the development of high quality National Rare Diseases Plans/Strategies in the European Union. Provide continued support for the International Rare Disease Research Consortium and initiatives developed under its umbrella. Continue to ensure proper codification of rare diseases. Work further to decrease inequalities between patients with rare diseases and patients suffering from more common disorders and to support initiatives promoting equal access to diagnosi ...[+++]s and treatment. Continue to promote patients empowerment in all aspects of rare diseases policy development Continue activities increasing public awareness about rare diseases and EU activity in this field Make use of the Directive 2011/24/EU on the application of patients’ rights in cross-border healthcare to bring together European Reference Networks on rare diseases. Support the development of the tools facilitating cooperation and interoperability of the European Reference Networks for rare diseases. Stimulate development and use of eHealth solutions in the area of rare diseases. Implement and continue support for the European Platform on rare diseases registration. Continue playing a global role in the rare diseases initiative and collaborating with important international stakeholders.